ACAD
ACADIA Pharmaceuticals Inc.
Price Chart
Latest Quote
$26.13
Current Price| Previous Close | $25.13 |
| Open | $25.29 |
| Day High | $26.23 |
| Day Low | $25.03 |
| Volume | 1,208,860 |
Stock Information
| Shares Outstanding | 169.18M |
| Total Debt | $54.81M |
| Cash Equivalents | $847.02M |
| Revenue | $1.05B |
| Net Income | $261.17M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $4.42B |
| P/E Ratio | 16.86 |
| EPS (TTM) | $1.55 |
| Exchange | NMS |
đ Custom Metrics & Score
Score: 27/42| Debt to Equity | 0.07 |
| Debt to Earnings | 0.06 |
| Current Ratio | 2.38 |
| Quick Ratio | 2.18 |
| Avg Revenue Growth | 24.46% |
| Profit Margin | 23.64% |
| Return on Equity | 30.90% |
| Avg FCF Growth | -56.00% |
| FCF Yield | 3.56% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $26.13 | 1,209,838 |
| 2026-01-30 | $25.13 | 1,210,200 |
| 2026-01-29 | $25.70 | 1,055,000 |
| 2026-01-28 | $25.62 | 1,500,900 |
| 2026-01-27 | $26.20 | 1,075,700 |
| 2026-01-26 | $26.86 | 596,100 |
| 2026-01-23 | $26.84 | 1,951,200 |
| 2026-01-22 | $27.51 | 1,611,200 |
| 2026-01-21 | $26.76 | 1,374,100 |
| 2026-01-20 | $26.29 | 1,248,800 |
| 2026-01-16 | $25.99 | 1,357,700 |
| 2026-01-15 | $26.53 | 998,200 |
| 2026-01-14 | $26.86 | 951,800 |
| 2026-01-13 | $26.46 | 1,140,700 |
| 2026-01-12 | $26.59 | 1,046,900 |
| 2026-01-09 | $26.78 | 756,900 |
| 2026-01-08 | $26.91 | 1,303,400 |
| 2026-01-07 | $27.42 | 1,614,000 |
| 2026-01-06 | $26.94 | 1,411,300 |
| 2026-01-05 | $26.15 | 1,427,400 |
About ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
đ° Latest News
Why Acadia (ACAD) is Poised to Beat Earnings Estimates Again
Zacks âĸ 2026-02-02T17:10:04Z
FTRE or ACAD: Which Is the Better Value Stock Right Now?
Zacks âĸ 2026-01-28T16:40:02Z
Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026?
Zacks âĸ 2026-01-26T15:15:00Z
High Growth Tech Stocks To Watch In The US January 2026
Simply Wall St. âĸ 2026-01-22T11:38:18Z
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Swings
Simply Wall St. âĸ 2026-01-14T16:08:24Z
Is It Time To Reassess ACADIA Pharmaceuticals (ACAD) After Its Recent Share Price Surge
Simply Wall St. âĸ 2026-01-14T10:10:42Z
ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Maps Key Remlifansirin Readouts at JPM Conf
MarketBeat âĸ 2026-01-13T19:06:55Z
Acadia Pharmaceuticals Focuses on Next-Gen Neuroscience
Bloomberg âĸ 2026-01-12T21:01:19Z
FTRE vs. ACAD: Which Stock Is the Better Value Option?
Zacks âĸ 2026-01-12T16:40:03Z
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Its Strong 1-Year Share Price Rally
Simply Wall St. âĸ 2025-12-20T23:07:54Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $81,841,000 | $41,638,000 | $10,166,000 | $19,141,000 |
| Cost Of Revenue | $81,841,000 | $41,638,000 | $10,166,000 | $19,141,000 |
| Total Revenue | $957,797,000 | $726,437,000 | $517,235,000 | $484,145,000 |
| Operating Revenue | $957,797,000 | $726,437,000 | $517,235,000 | $484,145,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Expenses | $873,518,000 | $799,816,000 | $740,831,000 | $654,584,000 |
| Other Income Expense | $148,338,000 | $5,109,000 | $3,542,000 | $2,329,000 |
| Other Non Operating Income Expenses | $1,823,000 | $5,109,000 | $3,542,000 | $2,329,000 |
| Net Non Operating Interest Income Expense | $25,458,000 | $17,234,000 | $6,610,000 | $591,000 |
| Operating Expense | $791,677,000 | $758,178,000 | $730,665,000 | $635,443,000 |
| General And Administrative Expense | - | - | - | $396,028,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $226,451,000 | $-61,286,000 | $-215,975,000 | $-167,870,000 |
| Net Interest Income | $25,458,000 | $17,234,000 | $6,610,000 | $591,000 |
| Interest Income | $25,458,000 | $17,234,000 | $6,610,000 | $591,000 |
| Normalized Income | $97,889,658 | $-61,286,000 | $-215,975,000 | $-167,870,000 |
| Net Income From Continuing And Discontinued Operation | $226,451,000 | $-61,286,000 | $-215,975,000 | $-167,870,000 |
| Total Operating Income As Reported | $230,794,000 | $-73,379,000 | $-223,596,000 | $-170,439,000 |
| Net Income Common Stockholders | $226,451,000 | $-61,286,000 | $-215,975,000 | $-167,870,000 |
| Net Income | $226,451,000 | $-61,286,000 | $-215,975,000 | $-167,870,000 |
| Net Income Including Noncontrolling Interests | $226,451,000 | $-61,286,000 | $-215,975,000 | $-167,870,000 |
| Net Income Continuous Operations | $226,451,000 | $-61,286,000 | $-215,975,000 | $-167,870,000 |
| Pretax Income | $258,075,000 | $-51,036,000 | $-213,444,000 | $-167,519,000 |
| Special Income Charges | $146,515,000 | $0 | $0 | - |
| Interest Income Non Operating | $25,458,000 | $17,234,000 | $6,610,000 | $591,000 |
| Operating Income | $84,279,000 | $-73,379,000 | $-223,596,000 | $-170,439,000 |
| Gross Profit | $875,956,000 | $684,799,000 | $507,069,000 | $465,004,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $1.36 | $-0.37 | $-1.34 | $-1.05 |
| Basic EPS | $1.37 | $-0.37 | $-1.34 | $-1.05 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $17,953,658 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-46,353,000 | $-67,827,000 | $-221,570,000 | $-167,095,000 |
| Total Unusual Items | $146,515,000 | $0 | $0 | - |
| Total Unusual Items Excluding Goodwill | $146,515,000 | $0 | $0 | - |
| Reconciled Depreciation | $15,883,000 | $5,552,000 | $2,026,000 | $3,344,000 |
| EBITDA (Bullshit earnings) | $100,162,000 | $-67,827,000 | $-221,570,000 | $-167,095,000 |
| EBIT | $84,279,000 | $-73,379,000 | $-223,596,000 | $-170,439,000 |
| Diluted Average Shares | $166,362,000 | $163,819,000 | $161,683,000 | $160,493,000 |
| Basic Average Shares | $165,717,000 | $163,819,000 | $161,683,000 | $160,493,000 |
| Diluted NI Availto Com Stockholders | $226,451,000 | $-61,286,000 | $-215,975,000 | $-167,870,000 |
| Tax Provision | $31,624,000 | $10,250,000 | $2,531,000 | $351,000 |
| Gain On Sale Of Ppe | $146,515,000 | $0 | $0 | - |
| Research And Development | $303,249,000 | $351,619,000 | $361,575,000 | $239,415,000 |
| Selling General And Administration | $488,428,000 | $406,559,000 | $369,090,000 | $396,028,000 |
| Other Gand A | - | - | - | $396,028,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $613,011,000 | $366,265,000 | $400,413,000 | $540,894,000 |
| Total Assets | $1,187,756,000 | $748,956,000 | $587,812,000 | $700,122,000 |
| Total Non Current Assets | $249,438,000 | $132,831,000 | $79,875,000 | $82,299,000 |
| Other Non Current Assets | $78,870,000 | $10,874,000 | $18,281,000 | $15,984,000 |
| Goodwill And Other Intangible Assets | $119,782,000 | $65,490,000 | $0 | $0 |
| Current Assets | $938,318,000 | $616,125,000 | $507,937,000 | $617,823,000 |
| Prepaid Assets | $55,681,000 | $39,091,000 | $21,398,000 | $23,892,000 |
| Inventory | $21,949,000 | $35,819,000 | $6,636,000 | $7,881,000 |
| Receivables | $104,695,000 | $102,350,000 | $63,080,000 | $65,344,000 |
| Accrued Interest Receivable | $5,956,000 | $4,083,000 | $885,000 | $978,000 |
| Accounts Receivable | $98,739,000 | $98,267,000 | $62,195,000 | $64,366,000 |
| Cash Cash Equivalents And Short Term Investments | $755,993,000 | $438,865,000 | $416,823,000 | $520,706,000 |
| Cash And Cash Equivalents | $319,589,000 | $188,657,000 | $114,846,000 | $147,435,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $51,995,000 | $57,205,000 | $62,000,000 | $64,430,000 |
| Long Term Debt And Capital Lease Obligation | $42,037,000 | $47,800,000 | $52,695,000 | $56,126,000 |
| Current Debt And Capital Lease Obligation | $9,958,000 | $9,405,000 | $9,305,000 | $8,304,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $454,963,000 | $317,201,000 | $187,399,000 | $159,228,000 |
| Total Non Current Liabilities Net Minority Interest | $60,093,000 | $62,947,000 | $61,769,000 | $63,160,000 |
| Other Non Current Liabilities | $18,056,000 | $15,147,000 | $9,074,000 | $7,034,000 |
| Current Liabilities | $394,870,000 | $254,254,000 | $125,630,000 | $96,068,000 |
| Payables And Accrued Expenses | $348,361,000 | $202,131,000 | $88,302,000 | $61,868,000 |
| Payables | $28,208,000 | $19,107,000 | $13,123,000 | $6,876,000 |
| Total Tax Payable | $12,016,000 | $1,564,000 | $377,000 | - |
| Accounts Payable | $16,192,000 | $17,543,000 | $12,746,000 | $6,876,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $732,793,000 | $431,755,000 | $400,413,000 | $540,894,000 |
| Total Equity Gross Minority Interest | $732,793,000 | $431,755,000 | $400,413,000 | $540,894,000 |
| Stockholders Equity | $732,793,000 | $431,755,000 | $400,413,000 | $540,894,000 |
| Gains Losses Not Affecting Retained Earnings | $292,000 | $24,000 | $-975,000 | $-192,000 |
| Other Equity Adjustments | $292,000 | $24,000 | $-975,000 | $-192,000 |
| Retained Earnings | $-2,204,386,000 | $-2,430,837,000 | $-2,369,551,000 | $-2,153,576,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $166,708,856 | $164,650,219 | $162,064,872 | $161,012,695 |
| Share Issued | $166,708,856 | $164,650,219 | $162,064,872 | $161,012,695 |
| Tangible Book Value | $613,011,000 | $366,265,000 | $400,413,000 | $540,894,000 |
| Invested Capital | $732,793,000 | $431,755,000 | $400,413,000 | $540,894,000 |
| Working Capital | $543,448,000 | $361,871,000 | $382,307,000 | $521,755,000 |
| Capital Lease Obligations | $51,995,000 | $57,205,000 | $62,000,000 | $64,430,000 |
| Total Capitalization | $732,793,000 | $431,755,000 | $400,413,000 | $540,894,000 |
| Additional Paid In Capital | $2,936,871,000 | $2,862,552,000 | $2,770,923,000 | $2,694,646,000 |
| Capital Stock | $16,000 | $16,000 | $16,000 | $16,000 |
| Common Stock | $16,000 | $16,000 | $16,000 | $16,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $42,037,000 | $47,800,000 | $52,695,000 | $56,126,000 |
| Current Capital Lease Obligation | $9,958,000 | $9,405,000 | $9,305,000 | $8,304,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $36,551,000 | $42,718,000 | $28,023,000 | $25,896,000 |
| Current Accrued Expenses | $320,153,000 | $183,024,000 | $75,179,000 | $54,992,000 |
| Net PPE | $50,786,000 | $56,467,000 | $61,594,000 | $66,315,000 |
| Accumulated Depreciation | $-10,217,000 | $-9,556,000 | $-8,097,000 | $-6,184,000 |
| Gross PPE | $61,003,000 | $66,023,000 | $69,691,000 | $72,499,000 |
| Leases | $3,746,000 | $3,746,000 | $3,696,000 | $3,696,000 |
| Construction In Progress | $523,000 | $0 | - | - |
| Other Properties | $46,571,000 | $51,855,000 | $55,573,000 | $58,268,000 |
| Machinery Furniture Equipment | $10,163,000 | $10,422,000 | $10,422,000 | $10,535,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $436,404,000 | $250,208,000 | $301,977,000 | $373,271,000 |
| Finished Goods | - | - | $1,926,000 | $1,114,000 |
| Work In Process | - | - | $4,427,000 | $6,767,000 |
| Raw Materials | - | - | $283,000 | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $157,196,000 | $-23,348,000 | $-114,035,000 | $-126,782,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $157,719,000 | $16,702,000 | $-114,035,000 | $-125,660,000 |
| Cash Flow From Continuing Operating Activities | $157,719,000 | $16,702,000 | $-114,035,000 | $-125,660,000 |
| Operating Gains Losses | $-146,515,000 | $-4,585,000 | $-3,542,000 | $-2,329,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-523,000 | $-40,050,000 | - | $-1,122,000 |
| Investing Cash Flow | $-30,538,000 | $31,998,000 | $73,241,000 | $-71,102,000 |
| Cash Flow From Continuing Investing Activities | $-30,538,000 | $31,998,000 | $73,241,000 | $-71,102,000 |
| Net Other Investing Changes | $146,515,000 | - | - | - |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $6,845,000 | $25,129,000 | $8,199,000 | $18,162,000 |
| Financing Cash Flow | $6,845,000 | $25,129,000 | $8,199,000 | $18,162,000 |
| Cash Flow From Continuing Financing Activities | $6,845,000 | $25,129,000 | $8,199,000 | $18,162,000 |
| Net Common Stock Issuance | $6,845,000 | $25,129,000 | $8,199,000 | $18,162,000 |
| Common Stock Issuance | $6,845,000 | $25,129,000 | $8,199,000 | $18,162,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Income Tax Paid Supplemental Data | $19,521,000 | $5,850,000 | $2,190,000 | $1,038,000 |
| End Cash Position | $328,359,000 | $194,427,000 | $120,616,000 | $153,205,000 |
| Beginning Cash Position | $194,427,000 | $120,616,000 | $153,205,000 | $331,798,000 |
| Effect Of Exchange Rate Changes | $-94,000 | $-18,000 | $6,000 | $7,000 |
| Changes In Cash | $134,026,000 | $73,829,000 | $-32,595,000 | $-178,600,000 |
| Net Investment Purchase And Sale | $-176,530,000 | $72,048,000 | $73,241,000 | $-69,980,000 |
| Sale Of Investment | $328,565,000 | $442,033,000 | $436,415,000 | $422,817,000 |
| Purchase Of Investment | $-505,095,000 | $-369,985,000 | $-363,174,000 | $-492,797,000 |
| Net Intangibles Purchase And Sale | $0 | $-40,000,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-523,000 | $-50,000 | $0 | $-1,122,000 |
| Purchase Of PPE | $-523,000 | $-50,000 | $0 | $-1,122,000 |
| Change In Working Capital | $4,155,000 | $18,133,000 | $37,991,000 | $-24,824,000 |
| Change In Other Current Liabilities | $-4,689,000 | $201,000 | $-5,876,000 | $-3,579,000 |
| Change In Other Current Assets | $7,619,000 | $5,736,000 | $6,518,000 | $6,297,000 |
| Change In Payables And Accrued Expense | $69,710,000 | $97,967,000 | $30,176,000 | $-10,072,000 |
| Change In Accrued Expense | $71,061,000 | $93,170,000 | $24,306,000 | $-8,455,000 |
| Change In Payable | $-1,351,000 | $4,797,000 | $5,870,000 | $-1,617,000 |
| Change In Account Payable | $-1,351,000 | $4,797,000 | $5,870,000 | $-1,617,000 |
| Change In Prepaid Assets | $-16,590,000 | $-17,693,000 | $2,494,000 | $1,802,000 |
| Change In Inventory | $-49,550,000 | $-28,808,000 | $2,415,000 | $-4,210,000 |
| Change In Receivables | $-2,345,000 | $-39,270,000 | $2,264,000 | $-15,062,000 |
| Changes In Account Receivables | $-472,000 | $-36,072,000 | $2,171,000 | $-16,119,000 |
| Stock Based Compensation | $67,049,000 | $66,421,000 | $68,201,000 | $63,615,000 |
| Amortization Of Securities | $-9,304,000 | $-7,533,000 | $-2,736,000 | $2,404,000 |
| Depreciation Amortization Depletion | $15,883,000 | $5,552,000 | $2,026,000 | $3,344,000 |
| Depreciation And Amortization | $15,883,000 | $5,552,000 | $2,026,000 | $3,344,000 |
| Amortization Cash Flow | $14,963,000 | $4,093,000 | $0 | $1,108,000 |
| Amortization Of Intangibles | $14,963,000 | $4,093,000 | $0 | $1,108,000 |
| Depreciation | $920,000 | $1,459,000 | $2,026,000 | $2,236,000 |
| Net Income From Continuing Operations | $226,451,000 | $-61,286,000 | $-215,975,000 | $-167,870,000 |
| Gain Loss On Investment Securities | - | $-4,585,000 | $-3,542,000 | $-2,329,000 |